Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tripadvisor Inc Common Stock — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Tripadvisor Inc Common Stock trades at $8.93 (market cap $1.02B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 7.4× Tripadvisor Inc Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tripadvisor Inc Common Stock for 58 Days on average.
| SYRE | TRIP | |
|---|---|---|
Market Cap | $7.52B | $1.02B |
Volume | 1,441,031 | 1,973,736 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $16.72 |
52-Week Low | $22.18 | $8.04 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $6.52B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TripAdvisor (TRIP) trades at $8.93, up 2.41% today but near its 52-week low of $8.27. The stock shows neutral technical signals with bearish moving averages. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 2.11%, though recent quarters show earnings misses. The P/E ratio of 218.5 reflects high valuation relative to earnings, while P/S of 0.57 suggests reasonable sales valuation. Analyst sentiment is mixed with 62.5% hold ratings.
The outlook remains cautious due to competitive pressures from AI travel tools and uneven demand. Upside exists if Viator performance improves and TheFork sale completes, but risks include persistent earnings volatility and market share erosion. The consensus price target of $13.58 offers 52% potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
